HER family in cancer progression: From discovery to 2020 and beyond-Reference-Cited by-同舟云学术

HER family in cancer progression: From discovery to 2020 and beyond

Published:2020 Issue: Volume: Page:109-160
ISSN:0065-230X
Container-title:Advances in Cancer Research
language:
Short-container-title:

Author:

Kumar Rakesh,George Bijesh,Campbell Marcia R.,Verma Nandini,Paul Aswathy Mary,Melo-Alvim Cecília,Ribeiro Leonor,Pillai M. Radhakrishna,da Costa Luis Marques,Moasser Mark M.

Publisher

Elsevier

Reference275 articles.

1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3;Abel;The Journal of Clinical Investigation,2013

2. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase;Adam;The Journal of Biological Chemistry,1998

3. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth;Agus;Cancer Cell,2002

4. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma;Alver;Oncotarget,2016

5. A TORC2-Akt feed-forward topology underlies HER3 resiliency in HER2-amplified cancers;Amin;Molecular Cancer Therapeutics,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress of protein kinase inhibitors derived from marine peptides for developing anticancer agents;Cellular Signalling;2024-09

2. Transmembrane helix interactions regulate oligomerization of the receptor tyrosine kinase EphA2;Journal of Biological Chemistry;2024-07

3. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review;TRANSL CANCER RES;2024

4. A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas;Animals;2024-05-07

5. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions;Biomedicine & Pharmacotherapy;2024-05